Progeroid syndrome patients with ZMPSTE24 deficiency could benefit when treated with rapamycin and dimethylsulfoxide
Authors:
Open Access
- 2 November 2016
- journal article
- Published by Cold Spring Harbor Laboratory in Cold Spring Harbor Molecular Case Studies
- Vol. 3 (1) , a001339
Abstract
Patients with progeroid syndromes such as mandibuloacral dysplasia, type B (MADB) and restrictive dermopathy (RD) harbor mutations in zinc metalloproteinase (ZMPSTE24), an enzyme essential for posttranslational proteolysis of prelamin A to form mature lamin A. Dermal fibroblasts from these patients show increased nuclear dysmorphology and reduced proliferation; however, the efficacy of various pharmacological agents in reversing these cellular phenotypes remains unknown. In this study, fibroblasts from MADB patients exhibited marked nuclear abnormalities and reduced proliferation that improved upon treatment with rapamycin and dimethylsulfoxide but not with other agents, including farnesyl transferase inhibitors. Surprisingly, fibroblasts from an RD patient with a homozygous null mutation in ZMPSTE24, resulting in exclusive accumulation of prelamin A with no lamin A on immunoblotting of cellular lysate, exhibited few nuclear abnormalities and near-normal cellular proliferation. An unbiased proteomic analysis of the cellular lysate from RD fibroblasts revealed a lack of processing of vimentin, a cytoskeletal protein. Interestingly, the assembly of the vimentin microfibrils in MADB fibroblasts improved with rapamycin and dimethylsulfoxide. We conclude that rapamycin and dimethylsulfoxide are beneficial for improving nuclear morphology and cell proliferation of MADB fibroblasts. Data from a single RD patient's fibroblasts also suggest that prelamin A accumulation by itself might not be detrimental and requires additional alterations at the cellular level to manifest the phenotype.Keywords
This publication has 64 references indexed in Scilit:
- Lifespan Control by Redox-Dependent Recruitment of Chaperones to Misfolded ProteinsCell, 2016
- The decision‐making process and criteria in selecting candidate drugs for progeria clinical trialsEMBO Molecular Medicine, 2016
- A simple tool to improve pluripotent stem cell differentiationNature Methods, 2013
- Protein profiling reveals energy metabolism and cytoskeletal protein alterations in LMNA mutation carriersBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2012
- The accumulation of un-repairable DNA damage in laminopathy progeria fibroblasts is caused by ROS generation and is prevented by treatment with N-acetyl cysteineHuman Molecular Genetics, 2011
- Mislocalization of prelamin A Tyr646Phe mutant to the nuclear pore complex in human embryonic kidney 293 cellsBiochemical and Biophysical Research Communications, 2007
- Loss of ZMPSTE24 (FACE-1) causes autosomal recessive restrictive dermopathy and accumulation of Lamin A precursorsHuman Molecular Genetics, 2005
- Open Mass Spectrometry Search AlgorithmJournal of Proteome Research, 2004
- Cellular senescence as a tumor-suppressor mechanismTrends in Cell Biology, 2001
- Cleavage of vimentin in dense cell culturesExperimental Cell Research, 1986